Medigene and Difa Cooper enter into agreement for the commercialization of Veregen® in Italy
06 8월 2013 - 2:31PM
Medigene AG / Medigene and Difa Cooper enter into agreement for
the commercialization of Veregen® in Italy . Ad hoc announcement
according to § 15 WpHG. Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of
this announcement.
Martinsried/Munich, 06
August, 2013. Medigene AG (MDG, Frankfurt, Prime Standard)
announces the conclusion of an exclusive license and supply
agreement with Difa Cooper SPA, the Italian subsidiary of the
Spanish pharmaceutical company IFC (Industrial Farmaceutica
Cantabria), for the supply and commercialization of
Veregen® in Italy.
After approval Difa Cooper will promote and distribute the drug for
the treatment of genital warts. In addition to a one-time upfront
payment, Medigene will also obtain revenues from milestone
payments, from the supply of the finished product, as well as
double-digit royalties on the future sales of Veregen®.
Dr. Frank
Mathias, Chief Executive Officer of Medigene AG, comments:
"We are glad that we will now be able to open up the Italian market
with this marketing partnership. Difa Cooper is a renowned Italian
pharmaceutical company with a focus on dermatology, and will
approach all relevant target groups with the drug. We have
established sales networks for Veregen® in almost all
European countries, and the drug is currently available on
prescription in six European countries."
Dr. Stefano
Fatelli, General Manager of Difa Cooper, of Difa Cooper,
adds: "This innovative ointment for the topical treatment of
genital warts complements our product portfolio and strengthens our
competitive position. We look forward to driving forward the
approval and commercialization of Veregen® in
Italy."
Veregen® is already
being marketed in the USA (by Fougera), in Germany, Austria and
Switzerland (by Abbott), in Spain (by Bial), in Serbia (by
Pharmanova) as well as in the Netherlands (by Will-Pharma) and
approved in further countries. Market approvals and the launch of
Veregen® in several
other countries are pending in 2013. The marketing authorization
application for Italy and the remaining European countries is in
preparation. Medigene has entered into several marketing
partnerships for Veregen® across Europe, Asia, and America, and is
planning to continue this global licensing strategy to further
leverage the product's market potential.
About Veregen®:
Veregen®, a topical
treatment for external genital or perianal warts, contains a
concentrate of catechins with a complex defined composition
extracted from green tea leaves. In its current treatment
guidelines for sexually transmitted diseases, the US Center for
Disease Control and Prevention recommends Sinecatechins 15%
ointment (Veregen®) as a
possible option for treating genital warts. In addition,
Sinecatechins 10% & 15% ointment (Veregen®) has
been included in the current European guideline on the treatment of
genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
Difa
Cooper: Difa Cooper is a pharmaceutical company
specializing in dermatology and has been operating in the Italian
pharmacies market for more than 50 years. It is part of the IFC
Group (Industrial Farmaceutica Cantabria) based in Madrid. IFC
develops, manufactures, and distributes dermatological products,
pharmaceuticals, cosmetics, nutritional supplements, and
technologies. The IFC sales network covers more than 50 countries
worldwide. For more information, please visit
http://www.difacooper.com.
Medigene
AG (Frankfurt: MDG, Prime Standard) is a publicly listed
biotech company headquartered in Martinsried/Munich, Germany.
Medigene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases. Medigene is the first
German biotech company to generate revenues from a marketed product
(Veregen®), which is
distributed by partner companies. Medigene also has two drug
candidates undergoing clinical trials, EndoTAG®-1 und
RhuDex®, and is
developing an innovative vaccine technology. For further details,
please visit www.medigene.com
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and Veregen® are registered trademarks of
Medigene AG. Polyphenon E® is a trademark of Mitsui
Norin Co., Ltd. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Medigene AG via Thomson Reuters ONE
HUG#1721187
Meridian Gold (NYSE:MDG)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Meridian Gold (NYSE:MDG)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
